Summary

Meet our Team at our booth #2 during Cell & Gene Therapy Manufacturing & Commercialization Europe, in Amsterdam, December 5-7, 2022! Don't miss our presentation on December 6 & in collaboration with DiNAMIQs!

Our team

 Maxime Dumont 
 Product Manager 
About Maxime Dumont
Product Manager
Aucune information.
 Jean-Thomas ISSENHUTH 
 Key Account Manager 
About Jean-Thomas ISSENHUTH
Key Account Manager
Aucune information.
 Maria Nicla Loviglio 
 Scientific Support Specialist 
About Maria Nicla Loviglio
Scientific Support Specialist
Aucune information.
 Carine MOREL 
 Operation Director  
About Carine MOREL
Operation Director
Aucune information.
 Lucie Perez 
 Marketing Specialist 
About Lucie Perez
Marketing Specialist
Aucune information.
 Jelena Vjetrovic 
 Key Account Manager 
About Jelena Vjetrovic
Key Account Manager
Aucune information.

Presentations

Seamless AAV Manufacturing to the Global Gene Therapy Community : December 6, 2022 at 12:20 – 12:35 CET/CEST

Presented by Goutham K Ganjam, Head of AAV Manufacturing, DiNAMIQs, Zurich, Switzerland

DiNAMIQs AAV manufacturing platform is based on triple plasmid transfection of suspension HEK293 with FectoVIR®-AAV in shake flasks, stir tank bioreactors (2L, 4L and 50L) and purified by chromatography. Aligned with GMP regulations, we provide your high-quality vectors and minimal changes moving forward to your clinical applications. With FectoVIR®-AAV based transfection we achieve 35-40% of final enriched AAV full fraction.

 

Poster

Development of a novel helper plasmid: one step closer to the next generation rAAV vectors

Eric Mauro, Jonathan Havard, Sylvain Julien, Laure Robert, Carine Morel, Patrick Erbacher

To broaden the use of rAAVs to treat a wider spectrum of monogenic diseas for small and larger indications, the aim is to improve specificity, safety and patient affordability. For this, it is key to improve rAAV production yields to decrease manufacturing costs, and improve functional titers to administer lower and safer doses. To this end, our research is focused on developing novel technologies to ensure manufacturing of high yielding rAAV using transient transfection, as well as enhancing features of the rAAV vectors that act on the overall size of packaged material and specificity of delivery.

Here we present our state-of-the art approach to designing new helper plasmids (phelpers) with the aim of improving both the infectiosity (TU/mL) and the quality (full/empty ratio) of the viral particle obtained from suspensions cultures. We took the opportunity to exploit our proprietary DNA assembly method technology, to rationally explore the synergies of multiple genetic features modularly assembled in synthetic plasmids. Comparison of the biological activity of several versions of rationally designed pHelpers led us to identify the optimal configuration able to outperform existing helper plasmids in every tested bioproduction conditions. Our ability to assemble tailor designed DNA plasmids and our expertise in developing scalable transfection solutions for rAAV manufacturing gives us potential to improve both productivity and specificity of gene therapy products.

 

 

Our solutions for both protein and virus production

FectoVIR®-AAV: for Recombinant AAV virus production in suspension cells.

PEIpro® product range for a scalable viral vector production for Gene & Cell therapy.

 

General information

Give your feedback!